title: LULL(ed) into complacency: a perspective on licenses and stem cell translational science.
abstract: The US has had a very successful model for facilitating the translation of a basic discovery to a commercial application. The success of the model has hinged on providing clarity on ownership of a discovery, facilitating the licensing process, providing adequate incentive to the inventors, and developing a self-sustaining model for reinvestment. In recent years, technological, political, and regulatory changes have put strains on this model and in some cases have hindered progress rather than facilitated it. This is particularly true for the nascent field of regenerative medicine. To illustrate this, I will describe the contributing practices of several different entities, including universities, repositories, patent trolls, and service providers. It is my hope that the scientific community will be motivated to coordinate efforts against these obstacles to translation.
authors: Mahendra S
authors: MS
authors: Rao
mesh_terms: D006801:Humans; D008004:Licensure / Q000331:legislation & jurisprudence / Q000592:standards*; D057170:Translational Research, Biomedical / Q000592:standards* / Q000639:trends
references: Regen Med. 2010 Jul;5(4):581-91
references: 20632861
references: Nat Methods. 2010 Jan;7(1):28-33
references: 20038953
references: Stem Cells Int. 2011;2011:498132
references: 21904557
references: Nat Biotechnol. 2011 Feb;29(2):115-6
references: 21301432
references: Minerva. 2011 Mar;49(1):25-46
references: 21475661
references: Nat Biotechnol. 2009 Nov;27(11):977-9
references: 19898444
references: J Cell Biochem. 2012 Oct;113(10):3061-8
references: 22573568
references: Nat Biotechnol. 2010 Apr;28(4):325-8
references: 20379173
references: Curr Opin Chem Biol. 2012 Aug;16(3-4):268-77
references: 22819644
references: PLoS One. 2012;7(4):e35824
references: 22545141
references: Stem Cells Transl Med. 2012 May;1(5):409-21
references: 23197820
references: Science. 2013 Feb 15;339(6121):823-6
references: 23287722
references: Recent Pat Regen Med. 2011;1(2):142-163
references: 23355961
references: BioDrugs. 2010 Apr 1;24(2):99-108
references: 20199125
references: PLoS One. 2013;8(1):e52068
references: 23300961
references: Science. 2013 Feb 15;339(6121):819-23
references: 23287718
references: Cell. 2009 Dec 11;139(6):1032-7
references: 20005794